YHLO

Focus on healthcare, better life with technology In May of 2021, YHLO has successfully launched IPO and listed on Shanghai Stock Exchange (Stock code: 688575).

YHLO (EST. 2008) is an innovative and steadfastly growing company of immunoassay solutions headquartered in Shenzhen, China, specialized in developing, manufacturing and distributing in-vitro diagnostic instruments and reagents by a team of experienced scientists and engineers.

13/09/2026

Every Moment Matters. Every Patient Matters. 📌

Sepsis can progress rapidly, making early recognition and timely action essential.

On World Sepsis Day, YHLO stands with healthcare professionals around the world in raising awareness and supporting better-informed care.

Recognize earlier. Act in time. Care with purpose.

🔗 Learn more about YHLO: https://en.szyhlo.com

11/09/2026

What Can a Routine Inflammatory Marker Tell Us Over Time? 🧐

Not every clinical question requires a complex answer. Sometimes, a well-established biomarker can provide valuable context when viewed alongside the patient's overall clinical picture.

CRP has long been part of routine inflammatory assessment, and following its changes over time can add perspective to ongoing clinical evaluation. 🔬

When do you find CRP most useful in clinical practice? 💬

Take a closer look at YHLO CRP in the poster. 👇

🔗 Learn more about YHLO: https://en.szyhlo.com

10/09/2026

When It Comes to Infection, Timing Matters.

Clinical conditions can change quickly, and a single result may only provide a snapshot of what is happening. Having timely information can help clinicians follow the evolving clinical picture and support ongoing evaluation. 🔬

PCT is an established biomarker that can provide valuable information during the assessment of infection and critical illness, with changes over time adding further clinical context.

With YHLO PCT, laboratories can integrate PCT testing into routine clinical workflows, supporting timely assessment and monitoring when it matters. 🧪 ⚙️

How do you incorporate PCT trends into your clinical assessment? 💬

Explore the poster for more details. 👇

🔗 Learn more about YHLO: https://en.szyhlo.com

09/09/2026

📌 3 Biomarkers. One Broader View of Inflammation.

Inflammatory conditions can evolve rapidly, and a single biomarker may not always capture the full clinical picture. Different biomarkers can offer different perspectives on the inflammatory response. By looking at complementary signals, clinicians can gain broader information to support clinical assessment.

With its Inflammation Panel, YHLO brings together IL-6, PCT, and CRP, offering complementary biomarker information for a more comprehensive approach to inflammatory assessment. 😀 ✨

When different signals come together, the clinical picture becomes clearer.

How does your lab currently combine IL-6, PCT, and CRP — as a panel, or ordered individually depending on the clinical question? 🧐

Explore the poster for more details. 👇

🔗 Learn more about YHLO: https://en.szyhlo.com

04/09/2026

🎥 Episode 5 – Zoé: A Connection Beyond Business

Welcome back to — a series where one image captures the moments that define what we stand for.

Meet Zoé – one of our dedicated sales colleagues. This photo was taken at the YHLO Global Partners Conference earlier this year in Changsha, where she met with one of our key partners.

She shared about the markets they serve, the challenges they face, and how they could work together — all in the span of a few days.

A few weeks later, she traveled to our partners' country for the first time — and experienced firsthand what true partnership meant.

It wasn't just about business. It was about trust, warmth, and a genuine sense of family.

Today, their teams continue to work closely — connected by shared purpose and a shared mission: Focus on healthcare, better life with technology. ✨

🔗 Learn more about YHLO: https://en.szyhlo.com

Diagnostic

02/09/2026

H1 2026 at a Glance | YHLO

🔬 New products.
📌 New research.
🤝 New partnerships.
📍 New milestones.

The first half of 2026 has been a busy and rewarding chapter for YHLO.

From expanding our diagnostic portfolio and advancing clinical research to strengthening global partnerships and connecting with the IVD community at major international events, we continued to move forward across multiple fronts.

Swipe through to revisit the milestones, innovations, and moments that defined our H1 2026. 👉

And this is just the beginning. 💪
The journey continues. ✨

🔗 Learn more about YHLO: https://en.szyhlo.com

31/08/2026

🎥 Episode 4 – Edward: A Visit That Opened Doors

Welcome back to — a series where one image captures the moments that define what we stand for.

Meet Edward – our Chief Scientist. This photo was taken with a laboratory manager from Ethiopia, after a lecture Edward gave during a visit.

The manager invited him to see their facility. Edward suggested a visit to China instead — to show him what a fully automated lab could look like.

That visit made a lasting impression. He saw the scale, the efficiency, and the technology that YHLO could bring to a modern lab — and he brought that vision back to Ethiopia.

That's what we believe in — sharing what's possible, not just selling what's available. 🤝 🌟

Stay tuned for more stories from our team. ✨

🔗 Learn more about YHLO: https://en.szyhlo.com

28/08/2026

Beyond AFP: Adding PIVKA-II to Your Liver Cancer Panel for AFP-Negative HCC Detection

AFP alone is not enough. In a significant proportion of hepatocellular carcinoma cases, AFP levels remain within the normal range, creating a blind spot in routine liver cancer screening. For clinical laboratories, adding PIVKA-II alongside established markers means closing that gap — without disrupting existing workflows.

YHLO's Liver Cancer Panel, combining AFP, PIVKA-II, CEA, and CA19-9 on the iFlash CLIA platform, offers:
🔹 A four-marker panel that supports the detection of both AFP-positive and AFP-negative HCC, reducing the risk of missed diagnoses
🔹 Broader tumor differentiation capability — covering hepatocellular carcinoma, cholangiocarcinoma, and metastatic liver lesions in a single automated run
🔹 Quantitative results with high reproducibility, validated in multicenter clinical studies

👇 See the poster for panel composition and performance data below.

🤝 YHLO. Expanding liver cancer detection capabilities on a single platform.

🔗 Learn more about YHLO: https://en.szyhlo.com

26/08/2026

When Liver Injury Has an Autoimmune Origin: The Value of a Targeted Serological Panel

Not all liver damage is caused by viral hepatitis or metabolic disease. When autoimmune mechanisms drive liver injury, the clinical picture can remain silent until significant damage has occurred. For clinical laboratories, having a dedicated autoimmune liver disease panel means providing clinicians with the serological evidence needed for differential diagnosis — without sending samples out for specialized testing.

YHLO's Autoimmune Liver Disease Panel, running on the iFlash CLIA platform, offers:
🔹 A comprehensive menu covering primary biliary cholangitis, autoimmune hepatitis, and overlap syndromes — all in a single automated run
🔹 Quantitative, reproducible results with high diagnostic specificity, validated in multicenter clinical studies
🔹 Seamless integration with YHLO's broader autoimmune and liver disease menus, consolidating specialty testing on one platform

👇 See the poster for panel composition and clinical performance data below.

🤝 YHLO. Bringing specialty autoimmune testing in-house — on one platform.

🔗 Learn more about YHLO: https://en.szyhlo.com

24/08/2026

Five Biomarkers, One Platform: Non-Invasive Liver Fibrosis Assessment on iFlash

For clinical laboratories, monitoring liver fibrosis often means choosing between invasive biopsy-based staging and non-invasive serological panels. The challenge is finding a solution that offers both clinical utility and workflow efficiency.

YHLO's Liver Fibrosis Panel, running on the iFlash CLIA platform, combines five key biomarkers in a single automated workflow:
🔹 HA, PIIINP, Type IV Collagen, Laminin, and CHI3L1 — covering multiple aspects of ECM remodeling and liver injury
🔹 Non-invasive, quantitative results with high reproducibility, supporting disease monitoring and therapy follow-up
🔹 One sample, one platform, one report — eliminating the need for separate systems or send-out testing

👇 See the poster for panel composition and performance data below.

🤝 YHLO. Expanding specialty testing capabilities on a single automated platform.

🔗 Learn more about YHLO: https://en.szyhlo.com

Address

YHLO Biopark, Baolong 2nd Road, Baolong Subdistrict
Shenzhen
518000

Telephone

+8675526601910

Website

https://en.szyhlo.com/

Alerts

Be the first to know and let us send you an email when YHLO posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to YHLO:

Want your practice to be the top-listed Clinic in Shenzhen?